Optical Coherence Tomography News and Research

RSS

NinePoint enters IP licensing agreement with Massachusetts General Hospital

NinePoint Medical, Inc., an emerging leader in the development of in vivo pathology medical devices, today announced it has entered into an intellectual property (IP) licensing agreement with Massachusetts General Hospital (MGH). Under the agreement, NinePoint has certain exclusive rights in multiple fields to 188 patents and patent applications owned by MGH.

13 Dec 2010

Tomophase receives FDA 510(k) clearance to market Optical Coherence Tomography Imaging System

Tomophase Corporation, developer of the non-invasive Optical Coherence Tomography Imaging System (OCTIS™) and other devices, announced today that it has received FDA 510(k) clearance to market OCTIS.

10 Dec 2010

Micell initiates enrollment in DESSOLVE I clinical trial of MiStent DES

Micell Technologies,™ Inc. today announced it has enrolled at Mercy Hospital in Auckland, New Zealand, the first patient in DESSOLVE I (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries), a first-in-human clinical trial of the company's investigational MiStent™ Drug Eluting Coronary Stent System (MiStent DES).

29 Nov 2010

OptiMedica's Catalys Precision Laser System improves precision in cataract surgery

Global ophthalmic device company OptiMedica Corp. has announced that results from a clinical study of its Catalys Precision Laser System were published in the peer-reviewed journal Science Translational Medicine.

18 Nov 2010

Tomophase to commercialize OCT Imaging System for pulmonary applications with QTDP award

Tomophase Corporation, a leading developer of minimally invasive optical coherence tomography (OCT) tissue imaging devices, announced that it has received an award from the Departments of the Treasury and Health and Human Services for the Qualifying Therapeutic Discovery Project (QTDP.)

8 Nov 2010

Novel drug-coated balloon technology adopted in niche applications across Europe: MRG

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, novel drug-coated balloon technology is being adopted in niche applications throughout Europe. This market will continue to grow as physicians increasingly use the technology in cases where other devices may not be suitable.

4 Nov 2010

Canon to preview CR-2 Digital Non-Mydriatic Retinal Camera at AAO Annual Meeting

Canon U.S.A., Inc., a leader in digital imaging, will preview the lightest Canon retinal camera to-date, the CR-2 Digital Non-Mydriatic Retinal Camera, at the American Academy of Ophthalmology's (AAO) Annual Meeting (October 16 - 19). In addition to the CR-2 retinal camera, which is awaiting FDA clearance, visitors will be able to explore the Company's current full line of ophthalmic solutions in the Canon booth (booth #: 2208).

15 Oct 2010

OptiMedica to feature Catalys Precision Laser System at Ophthalmology annual meeting

Global ophthalmic device company OptiMedica Corp. has announced that its Catalys Precision Laser System will be featured as part of four clinical presentations at the American Academy of Ophthalmology annual meeting in Chicago on October 16, 17 and 18.

13 Oct 2010

Clinical trial results of Genous Bio-engineered R stent, EPC capture technology presented at TCT 2010

OrbusNeich today announced that clinical trial results highlighting the company's Genous Bio-engineered R stent and its endothelial progenitor cell capture technology across challenging patient subsets were presented during a symposium titled "EPC Capture Technology: from Genous to Combo" at Transcatheter Cardiovascular Therapeutics 2010 in Washington.

27 Sep 2010

Lutonix presents data on Moxy Drug Coated Balloon Catheter at TCT meeting

Lutonix, Inc., headquartered in Minneapolis, MN, today announced six-month data from three separate drug coated balloon studies presented at the TransCatheter Therapeutics (TCT) meeting this week demonstrated the ability of the Moxy Drug Coated Balloon Catheter to inhibit restenosis in both peripheral and coronary arteries.

24 Sep 2010

St. Jude Medical to highlight OCT product platform at TCT meeting

St. Jude Medical, Inc., a global medical device company, will highlight recently launched technology, including its new Optical Coherence Tomography (OCT) product platform, at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, D.C.

23 Sep 2010

Volcano to end distribution agreement with Fukuda Desnhi in Japan

Volcano Corporation, a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, said today it has reached an agreement with Fukuda Desnhi Co., Ltd. to end its distribution agreement in Japan.

21 Sep 2010

Optical coherence tomography to penetrate intravascular ultrasound market: MRG

According to Millennium Research Group (MRG), the optical coherence tomography market will grow at an annual rate of almost 60% through 2015, spurred by physician adoption of this new technology that was launched in the US in May 2010.

16 Sep 2010

Promedior initiates PRM-151 Phase 2a clinical study in prevention of scarring post glaucoma filtration surgery

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today that it has initiated a Phase 2a clinical study of PRM-151 to evaluate the efficacy, safety, and tolerability of PRM-151 in preventing post-surgical scarring in glaucoma patients following glaucoma filtration surgery. There currently are no approved drugs for preventing post-surgical scarring in glaucoma, and there are no approved anti-fibrotic drug therapies in the U.S. or Europe for any fibrotic disease.

7 Sep 2010

CORDIS reports positive results from 10-year follow-up of CYPHER Sirolimus-eluting coronary stent study

Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today at European Society of Cardiology in Stockholm that the results of follow-up tests undertaken ten years after the first patient was treated with a CYPHER(R) Sirolimus-eluting coronary stent have proven outstanding long-term efficacy and safety and were published earlier this year in "JACC: Cardiovascular Interventions".

31 Aug 2010

New optical imaging technique holds potential to improve angioplasty

A new optical imaging technique described in the journal Review of Scientific Instruments, which is published by the American Institute of Physics, holds the potential to greatly improve angioplasty, a surgery commonly performed to treat patients with a partially or completely blocked coronary artery that restricts blood flow to the heart.

11 Aug 2010

Volcano second-quarter revenues increase 36% to record $73.5 million

Volcano Corporation, a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, said today that revenues in the second quarter of 2010 increased 36 percent versus revenues in the second quarter of 2009.

30 Jul 2010

St. Jude Medical acquires LightLab Imaging

St. Jude Medical, Inc., a global medical device company, today completed the previously announced acquisition of LightLab Imaging, Inc. for approximately $90 million in cash.

7 Jul 2010

Lantis Laser to merge with Perio-Imaging

Lantis Laser Inc., announced today that it has signed a Letter of Intent to merge with Perio-Imaging Inc., a private New York based company. The merger would be an all stock transaction and closing, among other conditions, would be subject to raising the required funding to complete the proposed merged company's product development program. The name of the new merged company will be announced upon closing.

16 Jun 2010

Optical coherence tomography shows promise for multiple sclerosis diagnosis

A quick, painless eye measurement shows promise as a way to diagnose multiple sclerosis in its very early stages, and to track the effectiveness of treatments, researchers from UT Southwestern Medical Center have found in a multicenter study.

8 Jun 2010